Chemical formula: C₂₁H₂₅N₃O₂S Molecular mass: 383.507 g/mol PubChem compound: 5002
Quetiapine interacts in the following cases:
As with other antipsychotics, caution should be exercised when quetiapine is prescribed in patients with cardiovascular disease or family history of QT prolongation. Also caution should be exercised when quetiapine is prescribed either with medicines known to increase QT interval, or with concomitant neuroleptics, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.
Concomitant administration of quetiapine and other serotonergic agents, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants may result in serotonin syndrome, a potentially life-threatening condition.
If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.
Norquetiapine, an active metabolite of quetiapine, has moderate to strong affinity for several muscarinic receptor subtypes. This contributes to ADRs reflecting anti-cholinergic effects when quetiapine is used at recommended doses, when used concomitantly with other medications having anti-cholinergic effects, and in the setting of overdose. Quetiapine should be used with caution in patients receiving medications having anti-cholinergic (muscarinic) effects. Quetiapine should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, intestinal obstruction or related conditions, increased intraocular pressure or narrow angle glaucoma.
Quetiapine is extensively metabolized by the liver. Therefore, it should be used with caution in patients with known hepatic impairment, especially during the initial dosing period.
Prolonged-release quetiapine:
Patients with hepatic impairment should be started on 50 mg/day. The dose can be increased in increments of 50 mg/day to an effective dose, depending on the clinical response and tolerability of the individual patient.
Immediate-release quetiapine:
Patients with known hepatic impairment should be started with 25 mg/day. The dosage should be increased daily with increments of 25-50 mg/day until an effective dosage, depending on the clinical response and tolerability of the individual patient.
The effects of quetiapine on human fertility have not been assessed. Effects related to elevated prolactin levels were seen in rats, although these are not directly relevant to humans.
In a multiple dose trial in patients to assess the pharmacokinetics of quetiapine given before and during treatment with carbamazepine (a known hepatic enzyme inducer), co-administration of carbamazepine significantly increased the clearance of quetiapine. This increase in clearance reduced systemic quetiapine exposure (as measured by AUC) to an average of 13% of the exposure during administration of quetiapine alone; although a greater effect was seen in some patients. As a consequence of this interaction, lower plasma concentrations can occur, which could affect the efficacy of quetiapine therapy.
The pharmacokinetics of lithium were not altered when co-administered with quetiapine.
In a 6-week, randomised, study of lithium and quetiapine prolonged-release tablets versus placebo and quetiapine prolonged-release tablets in adult patients with acute mania, a higher incidence of extrapyramidal related events (in particular tremor), somnolence, and weight gain were observed in the lithium add-on group compared to the placebo add-on group.
Co-administration of quetiapine and phenytoin (another microsomal enzyme inducer) caused a greatly increased clearance of quetiapine by approx. 450%. In patients receiving a hepatic enzyme inducer, initiation of quetiapine treatment should only occur if the physician considers that the benefits of quetiapine outweigh the risks of removing the hepatic enzyme inducer. It is important that any change in the inducer is gradual, and if required, replaced with a non-inducer (e.g. sodium valproate).
The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically relevant extent when co-administered. A retrospective study of children and adolescents who received valproate, quetiapine, or both, found a higher incidence of leucopenia and neutropenia in the combination group versus the monotherapy groups.
Concomitant use of quetiapine and thioridazine caused an increased clearance of quetiapine with approx. 70%.
In controlled clinical trials there was no difference in the incidence of seizures in patients treated with quetiapine or placebo. No data is available about the incidence of seizures in patients with a history of seizure disorder. As with other antipsychotics, caution is recommended when treating patients with a history of seizures.
Quetiapine treatment has been associated with orthostatic hypotension and related dizziness which, like somnolence has onset usually during the initial dose-titration period. Quetiapine should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or other conditions predisposing to hypotension. Dose reduction or more gradual titration should be considered if orthostatic hypotension occurs, especially in patients with underlying cardiovascular disease.
Dysphagia has been reported with quetiapine. Quetiapine should be used with caution in patients at risk for aspiration pneumonia.
A population-based retrospective study of quetiapine for the treatment of patients with MDD, showed an increased risk of death during use of quetiapine in patients aged >65 years. This association was not present when patients with PD were removed from the analysis. Caution should be exercised if quetiapine is prescribed to elderly patients with PD.
Patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Sleep apnoea syndrome has been reported in patients using quetiapine. In patients receiving concomitant central nervous system depressants and who have a history of or are at risk for sleep apnoea, such as those who are overweight/obese or are male, quetiapine should be used with caution.
Constipation represents a risk factor for intestinal obstruction. Constipation and intestinal obstruction have been reported with quetiapine. This includes fatal reports in patients who are at higher risk of intestinal obstruction, including those that are receiving multiple concomitant medications that decrease intestinal motility and/or may not report symptoms of constipation. Patients with intestinal obstruction/ileus should be managed with close monitoring and urgent care.
The moderate amount of published data from exposed pregnancies (i.e. between 300-1000 pregnancy outcomes), including individual reports and some observational studies do not suggest an increased risk of malformations due to treatment. However, based on all available data, a definite conclusion cannot be drawn. Animal studies have shown reproductive toxicity. Therefore, quetiapine should only be used during pregnancy if the benefits justify the potential risks.
Neonates exposed to antipsychotics (including quetiapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.
Based on very limited data from published reports on quetiapine excretion into human breast milk, excretion of quetiapine at therapeutic doses appears to be inconsistent. Due to lack robust data, a decision must be made whether to discontinue breast-feeding or to discontinue quetiapine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
The effects of quetiapine on human fertility have not been assessed. Effects related to elevated prolactin levels were seen in rats, although these are not directly relevant to humans.
Given its primary central nervous system effects, quetiapine may interfere with activities requiring mental alertness. Therefore, patients should be advised not to drive or operate machinery, until individual susceptibility to this is known.
The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine (≥10%) are somnolence, dizziness, headache, dry mouth, withdrawal (discontinuation) symptoms, elevations in serum triglyceride levels, elevations in total cholesterol (predominantly LDL cholesterol), decreases in HDL cholesterol, weight gain, decreased haemoglobin and extrapyramidal symptoms.
The incidences of ADRs associated with quetiapine therapy, are tabulated below (Table 1) according to the format recommended by the Council for International Organizations of Medical Sciences (CIOMS III Working Group 1995).
Table 1. ADRs associated with quetiapine therapy:
The frequencies of adverse events are ranked according to the following: Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100, rare (≥1/10,000, <1/1000), very rare (<1/10,000), and not known (cannot be estimated from the available data).
| SOC | Very Common | Common | Uncommon | Rare | Very Rare | Not known |
| Blood and lymphatic system disorders | Decreased haemoglobin20 | Leucopenia26, decreased neutrophil count, eosinophils increased25 | Neutropenia, Thrombocytopenia, Anaemia, platelet count decreased12 | Agranulocytosis24 | ||
| Immune system disorders | Hypersensitivity (including allergic skin reactions) | Anaphylactic reaction4 | ||||
| Endocrine disorders | Hyperprolactinaemia14, decreases in total T422, decreases in free T422, decreases in total T322, increases in TSH22 | Decreases in free T322, Hypothyroidism | Inappropriate antidiuretic hormone secretion | |||
| Metabolism and nutritional disorders | Elevations in serum triglyceride levels9,28 Elevations in total cholesterol (predominantly LDL cholesterol)10,28 Decreases in HDL cholesterol16,28, Weight gain7,28 | Increased appetite, blood glucose increased to hyperglycaemic levels5,28 | Hyponatraemia18, Diabetes Mellitus4 Exacerbation of pre-existing diabetes | Metabolic syndrome27 | ||
| Psychiatric disorders | Abnormal dreams and nightmares, Suicidal ideation and suicidal behaviour19 | Somnambulism and related reactions such as sleep talking and sleep related eating disorder | ||||
| Nervous system disorders | Dizziness3,15, somnolence1,15, headache, Extrapyramidal symptoms | Dysarthria | Seizure, Restless legs syndrome, Tardive dyskinesia4, Syncope3,15, Confusional state | |||
| Cardiac disorders | Tachycardia3, Palpitations21 | QT prolongation11,17 Bradycardia29 | Cardiomyopathy, Myocarditis | |||
| Eye disorders | Vision blurred | |||||
| Vascular disorders | Orthostatic hypotension3,15 | Venous thromboembolism | Stroke31 | |||
| Respiratory, thoracic and mediastinal disorder | Dyspnoea21 | Rhinitis | ||||
| Gastrointestinal disorders | Dry mouth | Constipation, dyspepsia, vomiting23 | Dysphagia6 | Pancreatitis, Intestinal obstruction/ Ileus | ||
| Hepatobiliary disorders | Elevations in serum alanine aminotransferase (ALT)2, Elevations in gamma-GT levels2 | Elevations in serum aspartate aminotransferase (AST)2 | Jaundice4 Hepatitis | |||
| Skin and subcutaneous tissue disorders | Angioedema4, Stevens- Johnson syndrome4 Toxic | Epidermal Necrolysis, Erythema Multiforme, Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)30, Cutaneous vasculitis | ||||
| Musculoskeletal and connective tissue disorders | Rhabdomyolysis | |||||
| Renal and urinary disorders | Urinary retention | |||||
| Pregnancy, puerperium and perinatal conditions | Drug withdrawal syndrome neonatal | |||||
| Reproductive system and breast disorders | Sexual dysfunction | Priapism, galactorrhoea, breast swelling, menstrual disorder | ||||
| General disorders and administration site conditions | Withdrawal (discontinuation) symptoms8 | Mild asthenia, peripheral oedema, irritability, pyrexia | Neuroleptic malignant syndrome, hypothermia | |||
| Investigations | Elevations in blood creatine phosphokinase13 |
1 Somnolence may occur, usually during the first two weeks of treatment and generally resolves with the continued administration of quetiapine.
2 Asymptomatic elevations (shift from normal to >3X ULN at any time) in serum transaminase (ALT, AST) or gamma-GT-levels have been observed in some patients administered quetiapine. These elevations were usually reversible on continued quetiapine treatment.
3 As with other antipsychotics with alpha1 adrenergic blocking activity, quetiapine may commonly induce orthostatic hypotension, associated with dizziness, tachycardia and, in some patients, syncope, especially during the initial dose-titration period.
4 Calculation of Frequency for these ADR's have only been taken from postmarketing data with the immediate-release formulation of quetiapine.
5 Fasting blood glucose ≥7.0 mmol/L (≥126 mg/dL) or a non-fasting blood glucose ≥11.1 mmol/L (≥200 mg/dL) on at least one occasion.
6 An increase in the rate of dysphagia with quetiapine vs. placebo was only observed in the clinical trials in bipolar depression.
7 Based on >7% increase in body weight from baseline. Occurs predominantly during the early weeks of treatment in adults.
8 The following withdrawal symptoms have been observed most frequently in acute placebo-controlled, monotherapy clinical trials, which evaluated discontinuation symptoms: insomnia, nausea, headache, diarrhoea, vomiting, dizziness, and irritability. The incidence of these reactions had decreased significantly after 1 week post-discontinuation.
9 Triglycerides ≥2.258 mmol/L (≥200 mg/dL) (patients ≥18 years of age) or ≥1.694 mmol/L (≥150 mg/dL) (patients <18 years of age) on at least one occasion.
10 Cholesterol ≥6.2064 mmol/L (≥240 mg/dL) (patients ≥18 years of age) or ≥5.172 mmol/L (≥200 mg/dL) (patients <18 years of age) on at least one occasion. An increase in LDL cholesterol of ≥0.769 mmol/L (≥30 mg/dL) has been very commonly observed. Mean change among patients who had this increase was ≥1.07 mmol/L (41.7 mg/dL).
11 See text below.
12 Platelets ≤100 x 109/L on at least one occasion.
13 Based on clinical trial adverse event reports of blood creatine phosphokinase increase not associated with neuroleptic malignant syndrome.
14 Prolactin levels (patients >18 years of age): >20 μg/L (>869.56 pmol/L) males; >30 μg/L (>1304.34 pmol/L) females at any time.
15 May lead to falls.
16 HDL cholesterol: ≤1.025 mmol/L (<40 mg/dL) males; ≤1.282 mmol/L (<50 mg/dL)
females at any time.
17 Incidence of patient who have a QTc shift from <450 msec to ≥450 msec with a ≥30 msec increase. In placebo-controlled trials with quetiapine, the mean change and the incidence of patients who have a shift to a clinically significant level is similar between quetiapine and placebo
18 Shift from> 132 mmol/L to ≤132 mmol/L on at least one occasion.
19 Cases of suicidal ideation and suicidal behaviours have been reported during quetiapine therapy or early after treatment discontinuation.
20 Decreased haemoglobin to 8.07 mmol/L (≤13 g/l) males, 7.45 mmol/L (≤12 g/l) females on at least one occasion occurred in 11% of quetiapine patients in all trials including open label extensions. For these patients, the mean maximum decrease in hemoglobin at any time was 1.50 g/l.
21 These reports often occurred in the setting of tachycardia, dizziness, orthostatic hypotension and/or underlying cardiac/respiratory disease.
22 Based on shifts from normal baseline to potentially clinically important value at any time post-baseline in all trials. Shifts in total T4, free T4, total T3 and free T3 are defined as <0.8 x LLN (pmol/L) and shift in TSH is >5 mIU/L at any time.
23 Based upon the increased rate of vomiting in elderly patients (≥65 years of age).
24 Based on shift in neutrophils from ≥ =1.5 x 109/L at baseline to <0.5 x 109/L at any time during treatment and based on patients with severe neutropenia (<0.5 x 109/L) and infection during all quetiapine clinical trials.
25 Based on shifts from normal baseline to potentially clinically important value at any time post-baseline in all trials. Shifts in eosinophils are defined as >1 x 109 cells/L at any time.
26 Based on shifts from normal baseline to potentially clinically important value at any time post-baseline in all trials. Shifts in WBCs are defined as ≤3 x 109 cells/L at any time.
27 Based on adverse event reports of metabolic syndrome from all clinical trials with quetiapine.
28 In some patients, a worsening of more than one of the metabolic factors of weight, blood glucose and lipids was observed in clinical studies.
29 May occur at or near initiation of treatment and be associated with hypotension and/or syncope. Frequency based on adverse event reports of bradycardia and related events in all clinical trials with quetiapine.
30 Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with quetiapine treatment.
31 Based on one retrospective non-randomised epidemiological study.
Cases of QT prolongation, ventricular arrhythmia, sudden unexplained death, cardiac arrest and torsades de pointes have been reported with the use of neuroleptics and are considered class effects.
The same ADRs described above for adults should be considered for children and adolescents. The following table summarises ADRs that occur in a higher frequency category in children and adolescents patients (10-17 years of age) than in the adult population or ADRs that have not been identified in the adult population.
Table 2. ADRs in children and adolescents associated with quetiapine therapy that occur in a higher frequency than adults, or not identified in the adult population:
The frequencies of adverse events are ranked according to the following: Very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000) and very rare (<1/10,000).
| SOC | Very Common | Common |
| Endocrine disorders | Elevations in prolactin | |
| Metabolism and nutritional disorders | Increased appetite | |
| Nervous system disorders | Extrapyramidal symptoms3 | Syncope |
| Vascular disorders | Increases in blood pressure2 | |
| Respiratory, thoracic and mediastinal disorders | Rhinitis | |
| Gastrointestinal disorders | Vomiting | |
| General disorders and administration site conditions | Irritability3 |
1 Prolactin levels (patients <18 years of age): >20 ug/L (>869.56 pmol/L) males; >26 ug/L (>1130.428 pmol/L) females at any time. Less than 1% of patients had an increase to a prolactin level >100 ug/L.
2 Based on shifts above clinically significant thresholds (adapted from the National Institutes of Health criteria) or increases >20 mmHg for systolic or >10 mmHg for diastolic blood pressure at any time in two acute (3-6 weeks) placebo-controlled trials in children and adolescents.
3 Note: The frequency is consistent to that observed in adults, but irritability might be associated with different clinical implications in children and adolescents as compared to adults.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.